BF066, a novel dual target antiplatelet agent without significant bleeding

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Pan, ChangE ^a,b   Wei, Xunbin ^b,c   Ye, Jianqin ^d   Liu, Guangda ^b   Zhang, Si ^d   Zhang, Yan ^d   Du, Hongguang ^e   Ding, Zhongren ^d  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE A2A RECEPTOR; ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; BF 066; CLOPIDOGREL; COLLAGEN; FIBRINOGEN; PHOSPHODIESTERASE; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTITHROMBOTIC ACTIVITY; ARTICLE; CELL SPREADING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN BINDING; PROTEIN SECRETION; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBUS; TREATMENT RESPONSE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENINE; ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; ARACHIDONIC ACID; ARTERIOLES; CHLORIDES; COLLAGEN; FERRIC COMPOUNDS; FIBRINOGEN; HEMORRHAGE; HUMANS; IMMOBILIZED PROTEINS; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTOR, ADENOSINE A2A; THROMBIN; THROMBOSIS;

EID: 84863994282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040451     Document Type: Article

References (33)

1. Kaplan ZS, Jackson SP, (2011) The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program 2011: 51-61.
2. Marcus AJ, Safier LB, (1993) Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J 7: 516-522.
3. Ruggeri ZM, (2002) Platelets in atherothrombosis. Nat Med 8: 1227-1234.
4. Fuster V, Chesebro JH, (1981) Antithrombotic therapy: role of platelet-inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets. (first of three parts). Mayo Clin Proc 56: 102-112.
5. Herman AG, (1998) Rationale for the combination of anti-aggregating drugs. Thromb Res 92: S17-21.
6. Tendera M, Wojakowski W, (2003) Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb Res 110: 355-359.
7. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, et al. (2012) Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial. Circulation.
8. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, et al. (2009) Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 119: 3207-3214.
9. Lee K, Kim JY, Yoo BS, Yoon J, Hong MK, et al. (2010) Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. J Thromb Haemost 8: 2577-2579.
10. Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, et al. (2012) Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery: The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study. Circ Cardiovasc Interv.
11. Zhang S, Hu L, Du H, Guo Y, Zhang Y, et al. (2010) BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb Haemost 104: 845-857.
12. Hu L, Fan Z, Du H, Ni R, Zhang S, et al. (2011) BF061, a novel antiplatelet and antithrombotic agent targeting P2Y receptor and phosphodiesterase. Thromb Haemost 106: 1203-1214.
13. Liu J, Pestina TI, Berndt MC, Steward SA, Jackson CW, et al. (2004) The roles of ADP and TXA in botrocetin/VWF-induced aggregation of washed platelets. J Thromb Haemost 2: 2213-2222.
14. Ding Z, Bynagari YS, Mada SR, Jakubowski JA, Kunapuli SP, (2009) Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists. J Thromb Haemost 7: 232-234.
15. Shankar H, Murugappan S, Kim S, Jin J, Ding Z, et al. (2004) Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. Blood 104: 1335-1343.
16. Banno F, Chauhan AK, Kokame K, Yang J, Miyata S, et al. (2009) The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood 113: 5323-5329.
17. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, et al. (2006) Systemic antithrombotic effects of ADAMTS13. J Exp Med 203: 767-776.
18. Su X, Mi J, Yan J, Flevaris P, Lu Y, et al. (2008) RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase. Blood 112: 592-602.
19. Gao G, Chen L, Dong B, Gu H, Dong H, et al. (2009) RhoA effector mDia1 is required for PI 3-kinase-dependent actin remodeling and spreading by thrombin in platelets. Biochem Biophys Res Commun 385: 439-444.
20. Stolla M, Stefanini L, Roden RC, Chavez M, Hirsch J, et al. (2011) The kinetics of alphaIIbbeta3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy. Blood 117: 1005-1013.
21. Gessi S, Varani K, Merighi S, Ongini E, Borea PA, (2000) A(2A) adenosine receptors in human peripheral blood cells. Br J Pharmacol 129: 2-11.
22. Zhao L, Bath P, Heptinstall S, (2001) Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol 134: 353-358.
23. Hu L, Fan Z, Du H, Ni R, Zhang S, et al. (2011) BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb Haemost 106: 1203-1214.
24. Cattaneo M, Lecchi A, (2007) Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 5: 577-582.
25. Dickinson NT, Jang EK, Haslam RJ, (1997) Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 323 (Pt 2): 371-377.
26. Ishii H, Kojima Y, Masuda Y, Takada K, Sugimoto K, et al. (2009) Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) is up-regulated by increase in intracellular cyclic AMP levels in cultured HepG2 cells. Thromb Haemost 102: 1204-1211.
27. Biscetti F, Pecorini G, Straface G, Arena V, Stigliano E, et al. (2012) Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. Int J Cardiol.
28. Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, et al. (2012) Pharmacodynamic effects of adjunctive cilostazol therapy in coronary artery disease patients on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus status. Catheter Cardiovasc Interv.
29. Gresele P, Momi S, Falcinelli E, (2011) Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 72: 634-646.
30. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, et al. (2010) A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 8: 817-827.
31. Li Z, Ajdic J, Eigenthaler M, Du X, (2003) A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. Blood 101: 4423-4429.
32. Hayashi H, Sudo T, (2009) Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets. Thromb Haemost 102: 327-335.
33. Orlowski E, Chand R, Yip J, Wong C, Goschnick MW, et al. (2009) A platelet tetraspanin superfamily member, CD151, is required for regulation of thrombus growth and stability in vivo. J Thromb Haemost 7: 2074-2084.